|
1
|
Meier F, Will S, Ellwanger U,
Schlagenhauff B, Schittek B, Rassner G and Garbe C: Metastatic
pathways and time courses in the orderly progression of cutaneous
melanoma. Br J Dermatol. 147:62–70. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Five-year survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 381:1535–1546. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, et al:
Five-year survival outcomes for patients with advanced melanoma
treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 30:582–588.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schadendorf D, Makki A, Stahr C, van Dyck
A, Wanner R, Scheffer GL, Flens MJ, Scheper R and Henz BM: Membrane
transport proteins associated with drug resistance expressed in
human melanoma. Am J Pathol. 147:1545–1552. 1995.PubMed/NCBI
|
|
7
|
Vinay DS, Ryan EP, Pawelec G, Talib WH,
Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, et
al: Immune evasion in cancer: Mechanistic basis and therapeutic
strategies. Semin Cancer Biol. 35 Suppl:S185–S198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Middleton MR, Grob JJ, Aaronson N,
Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates
A, et al: Randomized phase III study of temozolomide versus
dacarbazine in the treatment of patients with advanced metastatic
malignant melanoma. J Clin Oncol. 18:158–166. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klink AJ, Chmielowski B, Feinberg B, Ahsan
S, Nero D and Liu FX: Health care resource utilization and costs in
first-line treatments for patients with metastatic melanoma in the
United States. J Manag Care Spec Pharm. 25:869–877. 2019.PubMed/NCBI
|
|
12
|
Kandel M, Allayous C, Dalle S, Mortier L,
Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, et
al: Update of survival and cost of metastatic melanoma with new
drugs: Estimations from the MelBase cohort. Eur J Cancer.
105:33–40. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ottaviano M, De Placido S and Ascierto PA:
Recent success and limitations of immune checkpoint inhibitors for
cancer: A lesson from melanoma. Virchows Arch. 474:421–432. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Helmbach H, Kern MA, Rossmann E, Renz K,
Kissel C, Gschwendt B and Schadendorf D: Drug resistance towards
etoposide and cisplatin in human melanoma cells is associated with
drug-dependent apoptosis deficiency. J Invest Dermatol.
118:923–932. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soengas MS and Lowe SW: Apoptosis and
melanoma chemoresistance. Oncogene. 22:3138–3151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen KG, Valencia JC, Gillet JP, Hearing
VJ and Gottesman MM: Involvement of ABC transporters in
melanogenesis and the development of multidrug resistance of
melanoma. Pigment Cell Melanoma Res. 22:740–749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ichihashi N and Kitajima Y: Chemotherapy
induces or increases expression of multidrug resistance-associated
protein in malignant melanoma cells. Br J Dermatol. 144:745–750.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Knorr C, Pelz JO, Gohl J, Hohenberger W
and Meyer T: Expression of chemoresistance-related genes and heat
shock protein 72 in hyperthermic isolated limb perfusion of
malignant melanoma: An experimental study. J Oncol.
2010:1387582010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Helvoort A, Smith AJ, Sprong H,
Fritzsche I, Schinkel AH, Borst P and van Meer G: MDR1
P-glycoprotein is a lipid translocase of broad specificity, while
MDR3 P-glycoprotein specifically translocates phosphatidylcholine.
Cell. 87:507–517. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson ZL and Chen J: Structural basis of
substrate recognition by the multidrug resistance protein MRP1.
Cell. 168:1075–1085. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Izquierdo MA, Scheffer GL, Flens MJ,
Shoemaker RH, Rome LH and Scheper RJ: Relationship of LRP-human
major vault protein to in vitro and clinical resistance to
anticancer drugs. Cytotechnology. 19:191–197. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Robey RW, Pluchino KM, Hall MD, Fojo AT,
Bates SE and Gottesman MM: Revisiting the role of ABC transporters
in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chyb S, Raghu P and Hardie RC:
Polyunsaturated fatty acids activate the Drosophila light-sensitive
channels TRP and TRPL. Nature. 397:255–259. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aroke EN, Powell-Roach KL, Jaime-Lara RB,
Tesfaye M, Roy A, Jackson P and Joseph PV: Taste the pain: The role
of TRP channels in pain and taste perception. Int J Mol Sci.
21:59292020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bergdahl A, Gomez MF, Wihlborg AK, Erlinge
D, Eyjolfson A, Xu SZ, Beech DJ, Dreja K and Hellstrand P:
Plasticity of TRPC expression in arterial smooth muscle:
Correlation with store-operated Ca2+ entry. Am J Physiol Cell
Physiol. 288:C872–C880. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okamoto Y, Ohkubo T, Ikebe T and Yamazaki
J: Blockade of TRPM8 activity reduces the invasion potential of
oral squamous carcinoma cell lines. Int J Oncol. 40:1431–1440.
2012.PubMed/NCBI
|
|
27
|
Zhang W, Hirschler-Laszkiewicz I, Tong Q,
Conrad K, Sun SC, Penn L, Barber DL, Stahl R, Carey DJ, Cheung JY
and Miller BA: TRPM2 is an ion channel that modulates hematopoietic
cell death through activation of caspases and PARP cleavage. Am J
Physiol Cell Physiol. 290:C1146–C1159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Perraud AL, Takanishi CL, Shen B, Kang S,
Smith MK, Schmitz C, Knowles HM, Ferraris D, Li W, Zhang J, et al:
Accumulation of free ADP-ribose from mitochondria mediates
oxidative stress-induced gating of TRPM2 cation channels. J Biol
Chem. 280:6138–6148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jeong H, Kim YH, Lee Y, Jung SJ and Oh SB:
TRPM2 contributes to LPC-induced intracellular Ca2+
influx and microglial activation. Biochem Biophys Res Commun.
485:301–306. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Melzer N, Hicking G, Gobel K and Wiendl H:
TRPM2 cation channels modulate T cell effector functions and
contribute to autoimmune CNS inflammation. PLoS One. 7:e476172012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hara Y, Wakamori M, Ishii M, Maeno E,
Nishida M, Yoshida T, Yamada H, Shimizu S, Mori E, Kudoh J, et al:
LTRPC2 Ca2+-permeable channel activated by changes in
redox status confers susceptibility to cell death. Mol Cell.
9:163–173. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fonfria E, Marshall IC, Benham CD,
Boyfield I, Brown JD, Hill K, Hughes JP, Skaper SD and McNulty S:
TRPM2 channel opening in response to oxidative stress is dependent
on activation of poly(ADP-ribose) polymerase. Br J Pharmacol.
143:186–192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hopkins MM, Feng X, Liu M, Parker LP and
Koh DW: Inhibition of the transient receptor potential melastatin-2
channel causes increased DNA damage and decreased proliferation in
breast adenocarcinoma cells. Int J Oncol. 46:2267–2276. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koh DW, Powell DP, Blake SD, Hoffman JL,
Hopkins MM and Feng X: Enhanced cytotoxicity in triple-negative and
estrogen receptor positive breast adenocarcinoma cells due to
inhibition of the transient receptor potential melastatin-2
channel. Oncol Rep. 34:1589–1598. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zeng X, Sikka SC, Huang L, Sun C, Xu C,
Jia D, Abdel-Mageed AB, Pottle JE, Taylor JT and Li M: Novel role
for the transient receptor potential channel TRPM2 in prostate
cancer cell proliferation. Prostate Cancer Prostatic Dis.
13:195–201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao LY, Xu WL, Xu ZQ, Qi C, Li Y, Cheng
J, Liu LK, Wu YN, Gao J and Ye JH: The overexpressed functional
transient receptor potential channel TRPM2 in oral squamous cell
carcinoma. Sci Rep. 6:384712016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shiku H, Takahashi T and Oettgen HF: Cell
surface antigens of human malignant melanoma. II. Serological
typing with immune adherence assays and definition of two new
surface antigents. J Exp Med. 144:873–881. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pawelec G and Marsh SG: ESTDAB: A
collection of immunologically characterised melanoma cell lines and
searchable databank. Cancer Immunol Immunother. 55:623–627. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schadendorf D, Fichtner I, Makki A,
Alijagic S, Küpper M, Mrowietz U and Henz BM: Metastatic potential
of human melanoma cells in nude mice-characterization of phenotype,
cytokine secretion and tumour-associated proteins. Br J Cancer.
74:194–199. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bloethner S, Chen B, Hemminki K,
Müller-Berghaus J, Ugurel S, Schadendorf D and Kumar R: Effect of
common B-RAF and N-RAS mutations on global gene expression in
melanoma cell lines. Carcinogenesis. 26:1224–1232. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Berridge MV, Herst PM and Tan AS:
Tetrazolium dyes as tools in cell biology: New insights into their
cellular reduction. Biotechnol Annu Rev. 11:127–152. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiang X, Deng Z, Zhuang X, Ju S, Mu J,
Jiang H, Zhang L, Yan J, Miller D and Zhang HG: Grhl2 determines
the epithelial phenotype of breast cancers and promotes tumor
progression. PLoS One. 7:e507812012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hill K, McNulty S and Randall AD:
Inhibition of TRPM2 channels by the antifungal agents clotrimazole
and econazole. Naunyn Schmiedebergs Arch Pharmacol. 370:227–237.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Denda M, Fuziwara S, Inoue K, Denda S,
Akamatsu H, Tomitaka A and Matsunaga K: Immunoreactivity of VR1 on
epidermal keratinocyte of human skin. Biochem Biophys Res Commun.
285:1250–1252. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Marincsak R, Toth BI, Czifra G, Márton I,
Rédl P, Tar I, Tóth L, Kovács L and Bíró T: Increased expression of
TRPV1 in squamous cell carcinoma of the human tongue. Oral Dis.
15:328–335. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Alptekin M, Eroglu S, Tutar E, Sencan S,
Geyik MA, Ulasli M, Demiryurek AT and Camci C: Gene expressions of
TRP channels in glioblastoma multiforme and relation with survival.
Tumour Biol. 36:9209–9213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang
TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, et al: AMG 9810
[(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]
dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1)
antagonist with antihyperalgesic properties. J Pharmacol Exp Ther.
313:474–484. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Oh ST, Yang KJ, Kim YH, Bae JM, Park HJ,
Kim JW and Park YM: Increased immunoreactivity for TRPM8 in
cutaneous squamous cell carcinoma. J Cutan Pathol. 45:970–972.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hemida AS, Hammam MA, Heriz NAEM and
Shehata WA: Expression of transient receptor potential channel of
melastatin number 8 (TRPM8) in non-melanoma skin cancer: A clinical
and immunohistochemical study. J Immunoassay Immunochem.
42:620–632. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lashinger ES, Steiginga MS, Hieble JP,
Leon LA, Gardner SD, Nagilla R, Davenport EA, Hoffman BE, Laping NJ
and Su X: AMTB, a TRPM8 channel blocker: Evidence in rats for
activity in overactive bladder and painful bladder syndrome. Am J
Physiol Renal Physiol. 295:F803–F810. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Crowley PD and Gallagher HC: Clotrimazole
as a pharmaceutical: Past, present and future. J Appl Microbiol.
117:611–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
PubChem [Internet]. Bethesda (MD), .
National Library of Medicine (US), National Center for
Biotechnology Information; 2004. PubChem Compound Summary for CID
2812, Clotrimazole. Available from. https://pubchem.ncbi.nlm.nih.gov/compound/Clotrimazole
|
|
54
|
Cuttner J, Troy KM, Funaro L, Brenden R
and Bottone EJ: Clotrimazole treatment for prevention of oral
candidiasis in patients with acute leukemia undergoing
chemotherapy. Results of a double-blind study. Am J Med.
81:771–774. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Taudorf EH, Jemec GBE, Hay RJ and Saunte
DML: Cutaneous candidiasis-an evidence-based review of topical and
systemic treatments to inform clinical practice. J Eur Acad
Dermatol Venereol. 33:1863–1873. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zheng J, Liu F, Du S, Li M, Wu T, Tan X
and Cheng W: Mechanism for regulation of melanoma cell death via
activation of thermo-TRPV4 and TRPV2. J Oncol. 2019:73628752019.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yamamura H, Ugawa S, Ueda T, Morita A and
Shimada S: TRPM8 activation suppresses cellular viability in human
melanoma. Am J Physiol Cell Physiol. 295:C296–C301. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dratkiewicz E, Simiczyjew A,
Pietraszek-Gremplewicz K, Mazurkiewicz J and Nowak D:
Characterization of melanoma cell lines resistant to vemurafenib
and evaluation of their responsiveness to EGFR- and MET-inhibitor
treatment. Int J Mol Sci. 21:1132019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Penso J and Beitner R: Clotrimazole and
bifonazole detach hexokinase from mitochondria of melanoma cells.
Eur J Pharmacol. 342:113–117. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zancan P, Rosas AO, Marcondes MC,
Marinho-Carvalho MM and Sola-Penna M: Clotrimazole inhibits and
modulates heterologous association of the key glycolytic enzyme
6-phosphofructo-1-kinase. Biochem Pharmacol. 73:1520–1527. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chen SJ, Bao L, Keefer K, Shanmughapriya
S, Chen L, Lee J, Wang J, Zhang XQ, Hirschler-Laszkiewicz I, Merali
S, et al: Transient receptor potential ion channel TRPM2 promotes
AML proliferation and survival through modulation of mitochondrial
function, ROS, and autophagy. Cell Death Dis. 11:2472020.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hirschler-Laszkiewicz I, Chen SJ, Bao L,
Wang J, Zhang XQ, Shanmughapriya S, Keefer K, Madesh M, Cheung JY
and Miller BA: The human ion channel TRPM2 modulates neuroblastoma
cell survival and mitochondrial function through Pyk2, CREB, and
MCU activation. Am J Physiol Cell Physiol. 315:C571–C586. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Benzaquen LR, Brugnara C, Byers HR,
Gatton-Celli S and Halperin JA: Clotrimazole inhibits cell
proliferation in vitro and in vivo. Nat Med. 1:534–540. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Schadendorf D, Herfordt R and Czarnetzki
BM: P-glycoprotein expression in primary and metastatic malignant
melanoma. Br J Dermatol. 132:551–555. 1995. View Article : Google Scholar : PubMed/NCBI
|
